Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) P/B ratio
As of 5 November 2026, Bio-Techne Corp (TECH) trades at a P/B ratio of 5.4×. Over the past ten years it has ranged from 3.2× (May 2026) to 13.3× (September 2021); the current reading is higher than 47% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2026 | 5.2× | 23.74% |
| FY2025 | 4.2× | (22.63%) |
| FY2024 | 5.5× | (16.33%) |
| FY2023 | 6.5× | (18.36%) |
| FY2022 | 8.0× | (28.02%) |
| FY2021 | 11.1× | 52.03% |
| FY2020 | 7.3× | 7.67% |
| FY2019 | 6.8× | 31.76% |
| FY2018 | 5.1× | 11.50% |
| FY2017 | 4.6× | (3.19%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 5.2× | 33.41% |
| Mar 2026 | 3.9× | (14.04%) |
| Dec 2025 | 4.6× | 3.59% |
| Sep 2025 | 4.4× | 4.16% |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| IBRX ImmunityBio, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. compare | 1.7× |
| PCVX Vaxcyte, Inc. compare | 3.3× |
| TECH Bio-Techne Corp | 5.4× |
| KYMR Kymera Therapeutics, Inc. compare | 7.8× |
| CAI Caris Life Sciences,�Inc. compare | 12.7× |
| TGTX TG Therapeutics, Inc. compare | 13.6× |
| TWST Twist Bioscience Corporation compare | 17.1× |
| SMMT Summit Therapeutics PLC compare | 17.8× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement